Additional CAR NK cell targets being developed for hematologic malignancies include CD33, CD38, CD123, CD20, BCMA, CLL1, and FLT3 [58, 130, 133–138], and dual-target CARs such as CD19/20 or CD19/22. Here, CD19 is linked to hematologic disorder.